Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

NCT03082677 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Hematologic Malignancy
Lymphoid Hematologic Malignancy

Interventions

DRUG: Ixazomib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]